Cybin FY2026 EPS Estimate Increased by Cantor Fitzgerald

Cybin Inc. (NYSE:CYBN) – Analysts at Cantor Fitzgerald upped their FY2026 EPS estimates for shares of Cybin in a report released on Monday, August 18th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($2.77) per share for the year, up from their previous estimate of ($4.23). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cybin’s current full-year earnings is ($4.76) per share.

Separately, Canaccord Genuity Group reduced their price objective on shares of Cybin from $73.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $85.00.

Cybin Trading Up 0.2%

Shares of NYSE CYBN opened at $6.60 on Wednesday. Cybin has a 12-month low of $4.81 and a 12-month high of $13.88. The stock has a market capitalization of $155.69 million, a price-to-earnings ratio of -1.51 and a beta of 0.68. The firm’s 50-day moving average price is $7.74 and its 200-day moving average price is $7.60.

Institutional Trading of Cybin

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. National Bank of Canada FI raised its position in Cybin by 3,546.5% in the 1st quarter. National Bank of Canada FI now owns 5,251 shares of the company’s stock worth $33,000 after purchasing an additional 5,107 shares during the period. Marshall Wace LLP purchased a new position in shares of Cybin during the fourth quarter worth approximately $94,000. Cowa LLC increased its position in shares of Cybin by 12.8% during the second quarter. Cowa LLC now owns 13,200 shares of the company’s stock worth $111,000 after acquiring an additional 1,500 shares during the period. PEAK6 LLC purchased a new position in shares of Cybin during the first quarter worth approximately $167,000. Finally, Bank of America Corp DE increased its position in shares of Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after acquiring an additional 11,790 shares during the period. 17.94% of the stock is owned by hedge funds and other institutional investors.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.